Newcastle Disease Virus Vectored Chicken Infectious Anaemia Vaccine Induces Robust Immune Response in Chickens

Newcastle disease virus (NDV) strain R2B, with an altered fusion protein cleavage site, was used as a viral vector to deliver the immunogenic genes VP2 and VP1 of chicken infectious anaemia virus (CIAV) to generate a bivalent vaccine candidate against these diseases in chickens. The immunogenic genes of CIAV were expressed as a single transcriptional unit from the NDV backbone and the two CIA viral proteins were obtained as separate entities using a self-cleaving foot-and-mouth disease virus 2A protease sequence between them. The recombinant virus (rR2B-FPCS-CAV) had similar growth kinetics as that of the parent recombinant virus (rR2B-FPCS) in vitro with similar pathogenicity characteristics. The bivalent vaccine candidate when given in specific pathogen-free chickens as primary and booster doses was able to elicit robust humoral and cell-mediated immune (CMI) responses obtained in a vaccination study that was conducted over a period of 15 weeks. In an NDV and CIAV ELISA trial, there was a significant difference in the titres of antibody between vaccinated and control groups which showed slight reduction in antibody titre by 56 days of age. Hence, a second booster was administered and the antibody titres were maintained until 84 days of age. Similar trends were noticed in CMI response carried out by lymphocyte transformation test, CD4+ and CD8+ response by flow cytometry analysis and response of real time PCR analysis of cytokine genes. Birds were challenged with virulent NDV and CIAV at 84 days and there was significant reduction in the NDV shed on the 2nd and 4th days post challenge in vaccinated birds as compared to unvaccinated controls. Haematological parameters comprising PCV, TLC, PLC and PHC were estimated in birds that were challenged with CIAV that indicated a significant reduction in the blood parameters of controls. Our findings support the development and assessment of a bivalent vaccine candidate against NDV and CIAV in chickens.

Download Full-text

Evaluation of immunity and protection in chicken administered a developed vaccine against predominant Middle Eastern strains of genotypes VI and VII of velogenic Newcastle Disease Virus

10.21203/rs.3.rs-16483/v1 ◽

2020 ◽

Author(s):

Soonham Sami Yaghmoor` ◽

Taha Abdullah Kumosani ◽

Elie Kamil Barbour ◽

Othman Abubaker Baothman

Keyword(s):

Newcastle Disease Virus ◽

Disease Virus ◽

Humoral Immunity ◽

Newcastle Disease ◽

Middle Eastern ◽

Economic Losses ◽

Bivalent Vaccine ◽

Velogenic Newcastle Disease Virus ◽

Ifn Γ ◽

H Protein

Abstract Background The velogenic-Newcastle Disease Virus (v-NDV) causes an important disease in chicken, associated with serious economic losses to the global poultry industry. This research evaluated the immunity in broilers administered a developed bivalent vaccine, aiming at protection against predominant Middle Eastern strains of genotypes VI and VII of v-NDV. The completely randomized design implemented in this evaluation included eight treatments, differing in birds being administered or deprived of the developed vaccine, with a difference in type of challenge, either by v-NDV strain(s) of genotype VI, VII, or both. Vaccination was administered subcutaneously at 6 and 21 d of age, followed by an intra-pectoral challenge at the age of 28 d. Results The acquired humoral immunity by vaccinated and challenged birds to Hemagglutinin (H) protein was the highest at market age of 40 d, compared to challenged birds deprived of vaccination, and to vaccinates deprived of challenge (P<0.05). The same statistical difference pattern was obtained by the cell-mediated immunity (CMI), represented by birds’ level of serum IFN- γ . The type of challenge by either strain(s) of genotype VI, VII, or VI+VII did affect statistically the cross reactivity of acquired humoral immunity specific to H protein of homologous versus heterologous strains. The absence of humoral immunity and the low IFN- γ levels at 28 d of age in challenged birds deprived of vaccination lead to highest mortality, and lowest performance compared to vaccinates and challenged, vaccinates and deprived of challenge, and unvaccinated-unchallenged birds (P<0.05). Conclusions The developed bivalent vaccine was able to induce enough humoral and CMI responses, enabling protection of the broilers against production losses by each of the three types of v-NDV challenges. It is recommended to conduct future studies to evaluate such types of vaccines in chicken breeders and commercial layers, reared in various world’s zones with existing endemicity of v-NDV.

Download Full-text

Development and pre-clinical evaluation of Newcastle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate

10.1101/2021.03.07.434276 ◽

2021 ◽

Author(s):

Manolo Fernandez Díaz ◽

Katherine Calderon ◽

Aldo Rojas-Neyra ◽

Vikram N. Vakharia ◽

Ricardo Choque-Guevara ◽

...

Keyword(s):

Newcastle Disease Virus ◽

Disease Virus ◽

Newcastle Disease ◽

Vaccine Candidate ◽

Allantoic Fluid ◽

Cellular Damage ◽

Hamster Model ◽

Golden Syrian Hamster ◽

Oncological Treatment

ABSTRACTThe COVID-19 pandemic has claimed the lives of millions of people worldwide and threatens to become an endemic problem, therefore the need for as many types of vaccines as possible is of high importance.Because of the millions of doses required, it is desirable that vaccines are not only safe and effective, but also easy to administer, store, and inexpensive to produce.Newcastle Disease Virus (NDV) is responsible for a respiratory disease in chickens. It has no pathogenic homologue in humans. NDV is recognized as an oncolytic virus, and its use in humans for oncological treatment is being evaluated.In the present work, we have developed two types of NDV-vectored candidate vaccines, which carry the surface-exposed RBD and S1 antigens of SARS-CoV-2, respectively. These vaccine candidates were produced in specific-pathogen-free embryonating chicken eggs, and purified from allantoic fluid before lyophilization. These vaccines were administered intranasally to three different animal models: mice, rats and hamsters, and evaluated for safety, toxicity, immunogenicity, stability and efficacy. Efficacy was evaluated in a challenge assay against active SARS-CoV-2 virus in the Golden Syrian hamster model.The NDV-vectored vaccine based on the S1 antigen was shown to be safe and highly immunogenic, with the ability to neutralize SARS-CoV-2 in-vitro, even with an extreme dilution of 1/640. Our results reveal that this vaccine candidate protects the lungs of the animals, preventing cellular damage in this tissue. In addition, this vaccine reduces the viral load in the lungs, suggesting that it may significantly reduce the likelihood of transmission. Being lyophilized, this vaccine candidate is very stable and can be stored for several months at 4-8⁰C.In conclusion, our NDV-based vaccine candidate has shown a very favorable performance in the pre-clinical study, serving as evidence for a future evaluation in a Phase-I human clinical trial. This candidate represents a promising tool in the fight against COVID-19.

Download Full-text

Generation and evaluation of a vaccine candidate of attenuated and heat-resistant genotype VIII Newcastle disease virus

Poultry Science ◽

10.1016/j.psj.2020.01.034 ◽

2020 ◽

Vol 99 (7) ◽

pp. 3437-3444 ◽

Cited By ~ 1

Author(s):

Baoyang Ruan ◽

Qian Liu ◽

Yin Chen ◽

Xiaosai Niu ◽

Xuefeng Wang ◽

...

Keyword(s):

Newcastle Disease Virus ◽

Disease Virus ◽

Newcastle Disease ◽

Vaccine Candidate ◽

Resistant Genotype ◽

Heat Resistant

Download Full-text

Rapid Development of an Effective Newcastle Disease Virus Vaccine Candidate by Attenuation of a Genotype VII Velogenic Isolate Using a Simple Infectious Cloning System

Frontiers in Veterinary Science ◽

10.3389/fvets.2020.00648 ◽

2020 ◽

Vol 7 ◽

Author(s):

Nannan Wang ◽

Mei Huang ◽

To Sing Fung ◽

Qiong Luo ◽

Jun Xian Ye ◽

...

Keyword(s):

Newcastle Disease Virus ◽

Disease Virus ◽

Virus Vaccine ◽

Newcastle Disease ◽

Vaccine Candidate ◽

Rapid Development ◽

Cloning System ◽

Genotype Vii ◽

Newcastle Disease Virus Vaccine

Download Full-text

A Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects against NDV and IBDV

Journal of Virology ◽

10.1128/jvi.78.18.10054-10063.2004 ◽

2004 ◽

Vol 78 (18) ◽

pp. 10054-10063 ◽

Cited By ~ 102

Author(s):

Zhuhui Huang ◽

Subbiah Elankumaran ◽

Abdul S. Yunus ◽

Siba K. Samal

Keyword(s):

Newcastle Disease Virus ◽

Disease Virus ◽

Newcastle Disease ◽

Recombinant Virus ◽

Infectious Bursal Disease Virus ◽

Antibody Responses ◽

Infectious Bursal Disease ◽

Vp2 Protein ◽

Bursal Disease ◽

Recombinant Newcastle Disease Virus

ABSTRACT Infectious bursal disease virus (IBDV) causes a highly immunosuppressive disease in chickens. Currently available, live IBDV vaccines can lead to generation of variant viruses. We have developed an alternative vaccine that will not create variant IBDV. By using the reverse genetics approach, we devised a recombinant Newcastle disease virus (NDV) vector from a commonly used vaccine strain LaSota to express the host-protective immunogen VP2 of a variant IBDV strain GLS-5. The gene encoding the VP2 protein of the IBDV was inserted into the most 3′-proximal locus of a full-length NDV cDNA for high-level expression. We successfully recovered the recombinant virus, rLaSota/VP2. The rLaSota/VP2 was genetically stable, at least up to 12 serial passages in chicken embryos, and was shown to express the VP2 protein. The VP2 protein was not incorporated into the virions of recombinant virus. Recombinant rLaSota/VP2 replicated to a titer similar to that of parental NDV strain LaSota in chicken embryos and cell cultures. To assess protective efficacy of the rLaSota/VP2, 2-day-old specific-pathogen-free chickens were vaccinated with the recombinant virus and challenged with a highly virulent NDV strain Texas GB or IBDV variant strain GLS-5 at 3 weeks postvaccination. Vaccination with rLaSota/VP2 generated antibody responses against both NDV and IBDV and provided 90% protection against NDV and IBDV. Booster immunization induced higher levels of antibody responses against both NDV and IBDV and conferred complete protection against both viruses. These results indicate that the recombinant NDV can be used as a vaccine vector for other avian pathogens.

Download Full-text

Generation of a Genotype VII Newcastle Disease Virus Vaccine Candidate with High Yield in Embryonated Chicken Eggs

Avian Diseases Digest ◽

10.1637/9798-963311-digest.1 ◽

2011 ◽

Vol 6 (3) ◽

pp. e7-e8 ◽

Cited By ~ 1

Author(s):

Zenglei Hu ◽

Shunlin Hu ◽

Chun Meng ◽

Xiaoquan Wang ◽

Jie Zhu ◽

...

Keyword(s):

Newcastle Disease Virus ◽

Disease Virus ◽

Virus Vaccine ◽

Newcastle Disease ◽

Vaccine Candidate ◽

High Yield ◽

Chicken Eggs ◽

Embryonated Chicken ◽

Genotype Vii ◽

Newcastle Disease Virus Vaccine

Download Full-text

Preparation and bioactivity of anti-Newcastle disease virus-phosphoprotein cytoplasmic transduction peptide antibody

10.21203/rs.2.21452/v1 ◽

2020 ◽

Author(s):

Benqiang Li ◽

Man Wang ◽

Jianguo Zhu

Keyword(s):

Newcastle Disease Virus ◽

Disease Virus ◽

Newcastle Disease ◽

Protein Function ◽

Cell Protection ◽

Test Analysis ◽

Hiv Tat ◽

Significant Difference ◽

Macromolecular Protein ◽

And Control

Abstract On the basis of cell-penetrating peptide’s character that it can penetrate cytomembrane and transfer macromolecular protein to cytoplasm so to play biological function, we took the experiments. The fuse penetrating peptide our experiment adoptted is HIV-TAT derived fragment-CTP512, with good transmember effect and distinct cytoplasm-position. In this chapter, the research of transmembrane character was processed first. According to the tests on trans- member protein with different concentrations, the best trans-member concentration is 3µM. Afterwards, we found that the location of trans-member antibody is overlapping with phosphoprotein using indirect immunofluorescence test analysis. According to MTT test, there is no significant difference between CTP fusion protein and control on cell proliferation and viability. TCID50 test was used to detect the protective effect of trans-member antibody on cell. Result showed that trans- member antibody has significant cell protection effect compared to the control in the order: ZL.103>ZL.17>Control. Fluorogenic quantitative PCR result showed that trans- member antibody can disturb the duplication and transcription of Newcastle disease virus. This results not only paved a good way to research the transport of disease related protein, but also provide a splendid tool on protein function research.

Download Full-text